Statements (29)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:approvalYear |
2017
|
| gptkbp:approvedBy |
gptkb:FDA
|
| gptkbp:ATCCode |
H02AB13
|
| gptkbp:CASNumber |
14484-47-0
|
| gptkbp:chemicalFormula |
C25H31NO6
|
| gptkbp:drugClass |
gptkb:Corticosteroid
|
| gptkbp:form |
gptkb:tablet
oral suspension |
| gptkbp:genericName |
deflazacort
|
| https://www.w3.org/2000/01/rdf-schema#label |
Emflaza
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:manufacturer |
gptkb:PTC_Therapeutics
|
| gptkbp:marketedIn |
gptkb:United_States
|
| gptkbp:mechanismOfAction |
glucocorticoid receptor agonist
|
| gptkbp:pregnancyCategory |
C (US)
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
behavioral changes
cough frequent urination weight gain increased appetite upper respiratory tract infection cushingoid appearance |
| gptkbp:synonym |
deflazacort
|
| gptkbp:usedFor |
gptkb:Duchenne_muscular_dystrophy
|
| gptkbp:bfsParent |
gptkb:Marathon_Pharmaceuticals
gptkb:PTC_Therapeutics |
| gptkbp:bfsLayer |
7
|